Exited position

Christopher Bloomstran’s Pfizer (PFE) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Semper Augustus Investments Group LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2007Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares40.90KHighest verified quarter-end share count
Quarters reported19Verified quarters with shares above zero
What happened?

Semper Augustus Investments Group LLC first reported Pfizer in Q4 2007. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Semper Augustus Investments Group LLC sold the entire position in Q4 2012, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2012
Sold the entire position−9.60K shares · No shares reported at quarter-end
Q3 2012
Sold 76.5% of the position−31.30K shares · 9.60K shares remained
Filing context

Quarter-end price $24.89 · Estimated holding basis $20.34

Q2 2011
Bought 5.8% more+2.23K shares · 40.90K shares reported after the change
Filing context

Quarter-end price $20.61 · Estimated holding basis $20.34

Q4 2009
Bought 23.2% more+7.29K shares · 38.68K shares reported after the change
Filing context

Quarter-end price $18.20 · Estimated holding basis $21.88

Q2 2008
Sold 1.0% of the position−320 shares · 31.39K shares remained
Filing context

Quarter-end price $17.46 · Estimated holding basis $22.74

Q1 2008
New position+31.71K shares · 31.71K shares reported
Filing context

Quarter-end price $20.94 · Estimated holding basis $22.74

12 unchanged quarters are collapsed by default.

Portfolio importance

How important was Pfizer in Semper Augustus Investments Group LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.1%Q3 2012
Last reported rank#29of 33 reported positions
Peak portfolio weight0.6%Q4 2009
Best historical rank#28Q2 2011
At peak importanceQ4 2009
PFE
0.6%
Largest holding
13.3%
Cross-investor discovery

Who else owns Pfizer?

Also reported by 2 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
PFE0.1% of reported portfolio
Ray DalioBridgewater Associates, LP
PFE0.0% of reported portfolio
Explore Pfizer across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$27.552026-09-15

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Pfizer stock page →

This tracker follows Semper Augustus Investments Group LLC’s Form 13F disclosures, not Christopher Bloomstran’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.